Patents by Inventor Donald J. Treacy

Donald J. Treacy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240065985
    Abstract: Compositions and dosage forms that contain volatile lipophilic compounds, and methods of manufacturing such compositions and dosage forms, are described.
    Type: Application
    Filed: August 28, 2023
    Publication date: February 29, 2024
    Inventors: Amanda Karwic, Donald J. Treacy, JR., Bruce Artman, Edward M. Rudnic
  • Patent number: 8889187
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 18, 2014
    Assignee: Shionogi Inc.
    Inventors: Edward M Rudnic, James D Isbister, Donald J Treacy, Jr., Sandra E Wassink
  • Publication number: 20140212490
    Abstract: A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: SHIONOGI INC.
    Inventors: Bruce Cao, Sandra E. Wassink, Donald J. Treacy, JR., Beth A. Burnside, Colin E. Rowlings, John A. Bonck
  • Patent number: 8715727
    Abstract: A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: May 6, 2014
    Assignee: Shionogi Inc.
    Inventors: Bruce Cao, Sandra E. Wassink, Donald J. Treacy, Jr., Beth A. Burnside, Colin E. Rowlings, John A. Bonck
  • Patent number: 8303988
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: November 6, 2012
    Assignee: Shionogi Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Publication number: 20120035121
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
  • Publication number: 20110065718
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 17, 2011
    Applicant: Victory Pharma, Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, JR., Sandra E. Wassink
  • Patent number: 7282221
    Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: October 16, 2007
    Assignee: Middlebrook Pharmaceuticals, Inc.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7157095
    Abstract: An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: January 2, 2007
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7108859
    Abstract: An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: September 19, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7105174
    Abstract: An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-neoplastic product being reached in less than about twelve hours after initial release of anti-neoplastic from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: September 12, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7074417
    Abstract: An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the Cmax for the anti-viral product being reached in less than about twelve hours after initial release of anti-viral from the product.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: July 11, 2006
    Assignee: Advancis Pharmaceutical Corporation
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 7025989
    Abstract: An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: April 11, 2006
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6991807
    Abstract: Disclosed are antibiotic products for delivering at least two different antibiotics, wherein the products are comprised of at least three or four dosage forms with different release profiles and the at least two different antibiotics comprise at least one protein synthesis inhibiting antibiotic and at least one non-protein synthesis inhibiting antibiotic.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: January 31, 2006
    Assignee: Advancis Pharmaceutical, Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6984401
    Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: January 10, 2006
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6929804
    Abstract: An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: August 16, 2005
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Publication number: 20040219213
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Application
    Filed: January 16, 2004
    Publication date: November 4, 2004
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
  • Patent number: 6730320
    Abstract: An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 4, 2004
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: RE41148
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: February 23, 2010
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Edward M. Rudnic, Charlotte M. McGuinness
  • Patent number: RE42096
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: February 1, 2011
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic